# US 2025/0059267 A1 · Combination therapy for treatment of tumors comprising cancer-associated fibroblasts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059267 A1
- Document ID: US20250059267A1
- Status: Published application
- Kind: A1
- Application number: 18/568,262
- Filed: 2022-05-13
- Published: 2025-02-20
- Earliest claimed: 2021-05-14
- Applicants: Phenomic Ai
- Inventors: Sam COOPER; Allison NIXON; Max LONDON; Elizabeth KOCH; Arif JETHA; Christopher HARVEY; Michael BRISKIN
- Web page: https://patentgrep.com/patent/US20250059267A1

## CPC

- C07K 14/495: Transforming growth factor [TGF]
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/4747: {Apoptosis related proteins}
- C07K 14/59: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/71: for growth factors; for growth regulators
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides compositions and methods comprising at least one TGF-0 inhibitor and at least one Activin inhibitor for use in methods of treating CAF-enriched cancers and/or fibrotic disease.

## Claims

### Claim 1

A method for treating a solid tumor comprising cancer-associated fibroblasts (CAF) in a subject in need thereof, the method comprising simultaneously or sequentially administering to the subject a therapeutically effective dose of at least one TGF-β inhibitor and at least one Activin inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tumor is from a cancer selected from the group consisting of breast cancer, colon cancer, and pancreatic cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the TGF-β inhibitor and the Activin inhibitor are each independently selected from a peptidic inhibitor and an antibody inhibitor.

### Claim 4 (depends on 3)

The method of claim 3, wherein the TGF-β inhibitor is an antibody inhibitor selected from the group consisting of anti-TGF-β antibody clone 1D11, Fresolimumab, and LY3022859; and the Activin inhibitor is an antibody inhibitor selected from the group consisting of Garetosmab, and AMGA1, or the peptidic inhibitor Follistatin Fc.

### Claim 5 (depends on 3)

The method of claim 3, wherein the TGF-β inhibitor is an antibody inhibitor selected from the group consisting of anti-TGF-β antibody clone 1D11, Fresolimumab, and LY3022859; and the Activin inhibitor is an antibody inhibitor comprising a heavy chain variable region/light chain variable region (HCVR/LCVR) sequence pair selected from the group consisting of SEQ ID NOs: 433/434, 435/436, 437/438, 439/440, 441/442, 443/444, 445/446, 447/448, 449/450, 451/452, 453/454, 455/456, 457/458, 459/460, 461/462, 463/464, 465/466, 467/468, 469/470, 471/472, 473/474, 475/476, 477/478, 479/480, 481/482, 483/484, 485/486, 487/488, 489/490, 491/492, 493/494, 495/496, 497/498, 499/500, and 501/502; or
the Activin inhibitor is an antibody inhibitor comprising the six complementarity determining regions (CDRs) of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 433/434, 435/436, 437/438, 439/440, 441/442, 443/444, 445/446, 447/448, 449/450, 451/452, 453/454, 455/456, 457/458, 459/460, 461/462, 463/464, 465/466, 467/468, 469/470, 471/472, 473/474, 475/476, 477/478, 479/480, 481/482, 483/484, 485/486, 487/488, 489/490, 491/492, 493/494, 495/496, 497/498, 499/500, and 501/502.

### Claim 6 (depends on 1)

The method of claim 1, wherein the TGF-β inhibitor targets TGF-β 1.

### Claim 7 (depends on 5)

The method of claim 5, wherein the TGF-β inhibitor further targets TGF-β3.

### Claim 8 (depends on 1)

The method of claim 1, wherein the Activin inhibitor is an anti-activin A antibody.

### Claim 9 (depends on 8)

The method of claim 8, wherein the Activin inhibitor also inhibits activin B.

### Claim 10 (depends on 1)

The method of claim 1, wherein the administering is systemic administration.

### Claim 11 (depends on 10)

The method of claim 10, wherein the therapeutically effective doses of the TGF-β inhibitor and the Activin inhibitor when given in combination are lower than the therapeutically effective dose of either inhibitor given individually.

### Claim 12 (depends on 10)

The method of claim 10, wherein the therapeutically effective dose of the Activin inhibitor is higher than the therapeutically effective dose of the TGF-β inhibitor.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition further comprises an immune checkpoint inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the immune checkpoint inhibitor is a PD-1 checkpoint inhibitor.

### Claim 15

A method for inhibiting the transformation of normal tissue fibroblasts into cancer associated fibroblasts (CAFs) in a patient in need thereof, the method comprising simultaneously or sequentially administering to the patient at least one TGF-β inhibitor and at least one Activin inhibitor.

### Claim 16

A method of inhibiting growth of a solid tumor enriched in cancer-associated fibroblasts in a patient in need thereof, the method comprising simultaneously or sequentially administering to the patient at least one TGF-β inhibitor and at least one an Activin inhibitor.

### Claim 17 (depends on 16)

The method of claim 16, wherein the tumor is from a cancer selected from the group consisting of breast cancer, colon cancer, and pancreatic cancer.

### Claim 18 (depends on 15)

The method of claim 15, wherein the TGF-β inhibitor and the Activin inhibitor are each independently selected from a peptidic inhibitor and an antibody inhibitor.

### Claim 19 (depends on 18)

The method of claim 18, wherein the TGF-β inhibitor is an antibody inhibitor selected from the group consisting of anti-TGF-β antibody clone 1D11, Fresolimumab, and LY3022859; and the Activin inhibitor is an antibody inhibitor selected from the group consisting of Garetosmab, and AMGA1, or the peptidic inhibitor Follistatin Fc.

### Claim 20 (depends on 18)

The method of claim 18, wherein the TGF-β inhibitor is an antibody inhibitor selected from the group consisting of anti-TGF-β antibody clone 1D11, Fresolimumab, and LY3022859; and the Activin inhibitor is an antibody inhibitor comprising a heavy chain variable region/light chain variable region (HCVR/LCVR) sequence pair selected from the group consisting of SEQ ID NOs: 433/434, 435/436, 437/438, 439/440, 441/442, 443/444, 445/446, 447/448, 449/450, 451/452, 453/454, 455/456, 457/458, 459/460, 461/462, 463/464, 465/466, 467/468, 469/470, 471/472, 473/474, 475/476, 477/478, 479/480, 481/482, 483/484, 485/486, 487/488, 489/490, 491/492, 493/494, 495/496, 497/498, 499/500, and 501/502; or
the Activin inhibitor is an antibody inhibitor comprising the six complementarity determining regions (CDRs) of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 433/434, 435/436, 437/438, 439/440, 441/442, 443/444, 445/446, 447/448, 449/450, 451/452, 453/454, 455/456, 457/458, 459/460, 461/462, 463/464, 465/466, 467/468, 469/470, 471/472, 473/474, 475/476, 477/478, 479/480, 481/482, 483/484, 485/486, 487/488, 489/490, 491/492, 493/494, 495/496, 497/498, 499/500, and 501/502

### Claim 21 (depends on 15)

The method of claim 15 wherein the administering is systemic or intra-tumoral injection.

### Claim 22 (depends on 15)

The method of claim 15, wherein the composition further comprises an immune checkpoint inhibitor.

### Claim 23 (depends on 22)

The method of claim 22, wherein the immune checkpoint inhibitor is a PD-1 checkpoint inhibitor.

### Claim 24

A method for treating a fibrotic disease in a subject in need thereof, the method comprising simultaneously or sequentially administering to the subject a therapeutically effective dose of at least one TGF-β inhibitor and at least one Activin inhibitor.

### Claim 25 (depends on 24)

The method of claim 24, wherein the fibrotic disease is selected from the group consisting of Pulmonary Fibrosis (PF), Idiopathic Pulmonary Fibrosis (IPF), Liver Cirrhosis, Non-alcoholic steric hepatitis (NASH), Pulmonary Arterial Hypertension (PAH), Renal Fibrosis, Chronic Kidney Disease (CKD), Chronic Dermal Fibrosis, Scleroderma, Hypertrophic Scar, Cardiac Fibrosis, Hypertrophic Cardiomyopathy.

### Claim 26

A pharmaceutical composition comprising at least one TGF-β inhibitor and at least one Activin inhibitor in a pharmaceutically acceptable carrier.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the TGF-β inhibitor and the Activin inhibitor are each independently selected from a peptidic inhibitor and an antibody inhibitor.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the TGF-β inhibitor is an antibody inhibitor selected from the group consisting of anti-TGF-β antibody clone 1D11, Fresolimumab, and LY3022859; and the Activin inhibitor is an antibody inhibitor selected from the group consisting of Garetosmab, and AMGA1, or the peptidic inhibitor Follistatin Fc.

### Claim 29 (depends on 27)

The pharmaceutical composition of claim 27, wherein the TGF-β inhibitor is an antibody inhibitor selected from the group consisting of anti-TGF-β antibody clone 1D11, Fresolimumab, and LY3022859; and the Activin inhibitor is an antibody inhibitor comprising a heavy chain variable region/light chain variable region (HCVR/LCVR) sequence pair selected from the group consisting of SEQ ID NOs: 433/434, 435/436, 437/438, 439/440, 441/442, 443/444, 445/446, 447/448, 449/450, 451/452, 453/454, 455/456, 457/458, 459/460, 461/462, 463/464, 465/466, 467/468, 469/470, 471/472, 473/474, 475/476, 477/478, 479/480, 481/482, 483/484, 485/486, 487/488, 489/490, 491/492, 493/494, 495/496, 497/498, 499/500, and 501/502; or
the Activin inhibitor is an antibody inhibitor comprising the six complementarity determining regions (CDRs) of a HCVR/LCVR sequence pair selected from the group consisting of SEQ ID NOs: 433/434, 435/436, 437/438, 439/440, 441/442, 443/444, 445/446, 447/448, 449/450, 451/452, 453/454, 455/456, 457/458, 459/460, 461/462, 463/464, 465/466, 467/468, 469/470, 471/472, 473/474, 475/476, 477/478, 479/480, 481/482, 483/484, 485/486, 487/488, 489/490, 491/492, 493/494, 495/496, 497/498, 499/500, and 501/502

### Claim 30 (depends on 26)

The pharmaceutical composition of claim 26, further comprising an immune checkpoint inhibitor.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein the immune checkpoint inhibitor is a PD-1 checkpoint inhibitor.

### Claim at position 32

32-38. (canceled)
